Alumis Reaffirms Phase 3 Success but Valuation Ignores Looming Risks

What happened

Alumis reported year-end 2025 financial results, highlighting positive Phase 3 topline data for envudeucitinib in moderate-to-severe plaque psoriasis, which first emerged in January 2026. These results demonstrate leading skin clearance and a favorable safety profile through 24 weeks, supporting a planned NDA submission in the second half of 2026. However, the DeepValue master report notes that the stock has already surged over 245% to $24.17, pricing in not just approval but also meaningful optionality in lupus and neurology. Critical risks remain unaddressed, including twice-daily dosing versus once-daily competitors like Takeda's zasocitinib, high cash burn of approximately $400M annually, and the binary nature of upcoming lupus data in Q3 2026. Despite the positive spin, the current $2.5B market cap offers little margin of safety given no product revenue and fierce competition in the oral TYK2 inhibitor space.

Implication

The reaffirmation of envudeucitinib's Phase 3 data does not change the fundamental investment case, which already priced in this success and now faces asymmetric downside. Competition from once-daily oral therapies like Takeda's zasocitinib and J&J's icotrokinra could erode market share due to convenience, despite Alumis' comparable efficacy. With annualized cash burn near $400M and no revenue, further dilutive equity raises are likely before commercialization, pressuring shareholder value. Upcoming lupus data in Q3 2026 represents a critical catalyst that could break the multi-indication thesis if disappointing, given the stock's high expectations. Therefore, trimming above $28 or waiting for a pullback to $17 remains prudent to manage risk in this crowded, momentum-driven setup.

Thesis delta

No material shift in the investment thesis; the DeepValue report's 'POTENTIAL SELL' rating and asymmetric risk profile remain unchanged. The news confirms previously disclosed Phase 3 data but does not mitigate core concerns such as overvaluation, competitive disadvantages, or cash burn. Investors should maintain a cautious stance, with the thesis only improving if the price resets lower or new data demonstrate durable differentiation beyond current discounts.